Detalhe da pesquisa
1.
Real-World Evidence of Tolerability of 20% Subcutaneous Immunoglobulin Treatment.
J Clin Immunol
; 43(5): 912-920, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36809598
2.
Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension.
Am J Hypertens
; 17(6): 495-501, 2004 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15177521
3.
Efficacy and tolerability of a switch to fixed-dose combination therapy with amlodipine besylate/benazepril hydrochloride after monotherapy with amlodipine besylate: Data from the African-American subpopulation of a practice-based, open-label study (the LOGIC study).
Curr Ther Res Clin Exp
; 65(2): 138-48, 2004 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24936113
4.
Role of colesevelam in combination lipid-lowering therapy.
Am J Cardiovasc Drugs
; 13(5): 315-23, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23913404
5.
Atypical mechanism of glucose modulation by colesevelam in patients with type 2 diabetes.
Clin Med Insights Endocrinol Diabetes
; 6: 75-9, 2013 Dec 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-24348081